Physician profile
Craig A Alter
NPI 1295753515
$101,598.14
in general payments reported to CMS, 2019-2025
11 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,693 · 2020: $9,562 · 2021: $15K · 2022: $30K · 2023: $29K · 2024: $795 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Honoraria: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,300 · Travel and Lodging: $2,151 · Food and Beverage: $736 · Education: $19.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,478.50 |
| Honoraria | $15,338.20 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,300.00 |
| Travel and Lodging | $2,150.84 |
| Food and Beverage | $735.92 |
| Education | $19.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $42,400.00 | 2021-2023 | |
| Tolmar, INC. | $23,494.53 | 2023-2025 | Fensolvi |
| Pfizer INC. | $13,879.03 | 2022-2025 | |
| Tolmar Pharmaceuticals, INC. | $10,285.36 | 2020-2022 | |
| Novo Nordisk INC | $9,746.17 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $1,480.00 | 2020 | |
| Abbvie INC. | $140.81 | 2023 | Lupron Depot |
| Alexion Pharmaceuticals, INC. | $83.00 | 2019 | |
| Azurity Pharmaceuticals, INC. | $65.51 | 2023-2025 | Triptodur |
| Neurocrine Biosciences, INC. | $15.50 | 2025 | |
| Eton Pharmaceuticals, INC. | $8.23 | 2023 | Alkindi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Alter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.